Acute gout: The inflammasome.

Détails

ID Serval
serval:BIB_4A4FC3D033E7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Acute gout: The inflammasome.
Périodique
Current Rheumatology Reviews
Auteur(s)
Guarda G., Yazdi A.S., D'Ombrain M.C., Drexler S.K.
ISSN
1875-6360
ISSN-L
1573-3971
Statut éditorial
Publié
Date de publication
2011
Volume
7
Numéro
2
Pages
132-140
Langue
anglais
Résumé
Gout is one of the most common and painful forms of arthritis in humans with a growing incidence and prevalence over the last decades. Recent studies into the pathophysiology of acute gout have revealed that MSU (monosodium urate), the crystalline form of uric acid, is recognized by immune cells as a danger signal and can initiate an inflammatory response. This response is orchestrated by the intracellular pattern-recognition receptor NLRP3, which upon exposure to MSU, forms a cytosolic multiprotein-complex called the inflammasome, leading to the activation of caspase- 1. Caspase-1 then cleaves the highly pro-inflammatory cytokines interleukin (IL)-1β and IL-18, leading to the secretion of their biologically active forms and culminating in an acute gout attack. This newfound molecular understanding of the pathology of gout has seen the introduction of IL-1 inhibitors as an improved treatment for acute gout with reduced side effects compared to conventional gout therapies.
Mots-clé
IL-1β, Lesch-Nyhan-Syndrome, SLC2A9, Uric acid, Xenopus oocytes, caspase-1, hyperuricemia, inflammasome, leukemias, monosodium urate, polycythemia
Création de la notice
13/03/2012 15:51
Dernière modification de la notice
20/08/2019 13:58
Données d'usage